Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

New anti-Gram-positive agents.

D C Hamilton1, H Ludlam

  • 1Microbiology and Public Health Laboratory, Addenbrooke's Hospital, Hills Road, Cambridge 01223 257035, UK. dave.hamilton1@virgin.net

Current Opinion in Critical Care
|September 26, 2001
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Energetic Oxygen and Sulfur Charge States in the Outer Jovian Magnetosphere: Insights From the Cassini Jupiter Flyby.

Geophysical research letters·2020
Same author

Dust grains fall from Saturn's D-ring into its equatorial upper atmosphere.

Science (New York, N.Y.)·2018
Same author

Search for the exit: Voyager 1 at heliosphere's border with the galaxy.

Science (New York, N.Y.)·2013
Same author

Heterogeneous disease modeling for Hardy-Weinberg disequilibrium in case-control studies: application to renal stones and calcium-sensing receptor polymorphisms.

Annals of human genetics·2009
Same author

Mediation of the solar wind termination shock by non-thermal ions.

Nature·2008
Same author

Testing for equality of standardized composite measures of linkage disequilibrium.

Annals of human genetics·2007
Same journal

Cardiogenic shock - toward phenotype-directed, precision management.

Current opinion in critical care·2026
Same journal

The future of critical care nutrition: from calorie counting to precision personalized metabolism therapy.

Current opinion in critical care·2026
Same journal

Editorial introduction.

Current opinion in critical care·2026
Same journal

Generative artificial intelligence for outcome prediction in critical care: the future is now?

Current opinion in critical care·2026
Same journal

Feeding under support in critical care illness: metabolic and nutritional management during extracorporeal membrane oxygenation and continuous renal replacement therapy.

Current opinion in critical care·2026
Same journal

Multinational collaborations in critical care research: feasible and useful?

Current opinion in critical care·2026
See all related articles

The rise of resistant Gram-positive infections in critical care units necessitates new treatments. While new agents offer promise, the challenge of antimicrobial resistance and the need for effective therapies continue to grow.

Area of Science:

  • Critical care medicine
  • Infectious diseases
  • Pharmacology

Background:

  • Increasing prevalence of antibiotic-resistant Gram-positive organisms in critical care units.
  • Associated rise in morbidity, mortality, and treatment costs.
  • Limitations of current treatments, including glycopeptides, due to resistance and pharmacokinetics.

Purpose of the Study:

  • To review the challenges posed by resistant Gram-positive organisms in critical care.
  • To discuss current and emerging therapeutic options.
  • To project future trends in antimicrobial therapy and resistance.

Main Methods:

  • Literature review of studies on Gram-positive resistance in critical care.
  • Analysis of current treatment guidelines and emerging antimicrobial agents.

Related Experiment Videos

  • Discussion of pharmacokinetic properties and clinical benefits of various agents.

    • Main Results:

    • Glycopeptide effectiveness is limited by increasing resistance and suboptimal pharmacokinetics.
    • Newer agents like quinupristin/dalfopristin and Linezolid show promise.
    • Diverse agents are in development, suggesting expanded therapeutic choices.

    Conclusions:

    • The emergence of resistant Gram-positive bacteria presents a significant clinical challenge.
    • New antimicrobial agents offer improved efficacy and broader therapeutic options.
    • Anticipation of greater therapeutic choice, alongside the ongoing threat of further resistance development.